Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Disease Progression × regorafenib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 105 Carcinoma, Hepatocellular 34 Neoplasm Metastasis 19 Neoplasms 16 Gastrointestinal Stromal Tumors 16 Colonic Neoplasms 14 Rectal Neoplasms 12 Liver Neoplasms 8 Glioblastoma 7 Sarcoma 6 Stomach Neoplasms 5 Sarcoma, Ewing 5 Ovarian Neoplasms 5 Osteosarcoma 5 Melanoma 5 Adenocarcinoma 5 Pancreatic Neoplasms 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Carcinoma, Renal Cell 4 Carcinoma, Non-Small-Cell Lung 4 Small Cell Lung Carcinoma 3 Rhabdomyosarcoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Leukemia, Myeloid, Acute 3 Colorectal Cancer Metastatic 3 Carcinoma, Transitional Cell 3 Carcinoma 3 Advanced Colorectal Cancer 3 Thyroid Neoplasms 2

Interventions

Lenalidomide 4 Gemcitabine 4 Dexamethasone 4 Cyclophosphamide 4 Bortezomib 4 Nivolumab 3 Cisplatin 3 Carboplatin 3 vandetanib 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 2 pomalidomide 2 pembrolizumab 2 liposomal doxorubicin 2 fludarabine 2 durvalumab 2 capivasertib 2 Radiosurgery 2 Paclitaxel 2 Doxorubicin 2 Bevacizumab 2 Anthropogenic Effects 2 venetoclax 1 umbralisib 1 ublituximab 1 tremelimumab 1 tivozanib 1 ricolinostat 1 regorafenib 1 pazopanib 1 niraparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07514455 2026-04-07

RECOMEND

Asan Medical Center

Phase 2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡